Formestane: Difference between revisions

	WikiDoc Resources for Formestane
Articles
Most recent articles on Formestane Most cited articles on Formestane Review articles on Formestane Articles on Formestane in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Formestane Images of Formestane Photos of Formestane Podcasts & MP3s on Formestane Videos on Formestane
Evidence Based Medicine
Cochrane Collaboration on Formestane Bandolier on Formestane TRIP on Formestane
Clinical Trials
Ongoing Trials on Formestane at Clinical Trials.gov Trial results on Formestane Clinical Trials on Formestane at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Formestane NICE Guidance on Formestane NHS PRODIGY Guidance FDA on Formestane CDC on Formestane
Books
Books on Formestane
News
Formestane in the news Be alerted to news on Formestane News trends on Formestane
Commentary
Blogs on Formestane
Definitions
Definitions of Formestane
Patient Resources / Community
Patient resources on Formestane Discussion groups on Formestane Patient Handouts on Formestane Directions to Hospitals Treating Formestane Risk calculators and risk factors for Formestane
Healthcare Provider Resources
Symptoms of Formestane Causes & Risk Factors for Formestane Diagnostic studies for Formestane Treatment of Formestane
Continuing Medical Education (CME)
CME Programs on Formestane
International
Formestane en Espanol Formestane en Francais
Business
Formestane in the Marketplace Patents on Formestane
Experimental / Informatics
List of terms related to Formestane

Formestane
Clinical data
Synonyms	4-hydroxyandrost-4-ene-3,17-dione
AHFS/Drugs.com	International Drug Names
ATC code	L02BG02 (WHO) ;
Identifiers
	IUPAC name (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione;
CAS Number	566-48-3 ;
PubChem CID	11273;
ChemSpider	10799 ;
UNII	PUB9T8T355;
KEGG	D07260 ;
ChEBI	CHEBI:75172 ;
ChEMBL	ChEMBL132530 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C19H26O3
Molar mass	302.408 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4;
	InChI InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1 ; Key:OSVMTWJCGUFAOD-KZQROQTASA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 14:37, 13 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Formestane (Lentaron) is a type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection.

Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor.

Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.

It is selective.

References

@@ Line 1: / Line 1: @@
-{{Editor Help}}
+{{Drugbox
+| Verifiedfields = changed
+| verifiedrevid = 437193284
+| IUPAC_name = (8''R'',9''S'',10''R'',13''S'',14''S'')-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthrene-3,17-dione
+| image = Formestane1.png
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|formestane}}
+| pregnancy_category =
+| legal_status =
+| routes_of_administration =
-{{Drugbox|
+<!--Pharmacokinetic data-->
-|IUPAC_name = (8''R'',9''S'',10''R'',13''S'',14''S'')-4-hydroxy-10,13-dimethyl-<br>2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-<br>cyclopenta[a]phenanthrene-3,17-dione
+| bioavailability =
-| image= Formestane.png
+| metabolism =
-| CAS_number=566-48-3
+| excretion =
-| ATC_prefix=L02
-| ATC_suffix=BG02
+<!--Identifiers-->
-| ATC_supplemental=
+| CAS_number_Ref = {{cascite|correct|??}}
-| PubChem=11273
+| CAS_number = 566-48-3
-| DrugBank=
+| ATC_prefix = L02
-| C = 19 | H = 26 | O = 3
+| ATC_suffix = BG02
+| PubChem = 11273
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 10799
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = PUB9T8T355
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D07260
+| ChEBI_Ref = {{ebicite|changed|EBI}}
+| ChEBI = 75172
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 132530
+<!--Chemical data-->
+| C=19 | H=26 | O=3
 | molecular_weight = 302.408 g/mol
-| bioavailability=
+| smiles = O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4
-| metabolism =
+| InChI = 1/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
-| elimination_half-life=
+| InChIKey = OSVMTWJCGUFAOD-KZQROQTABI
-| excretion =
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-| pregnancy_category =
+| StdInChI = 1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
-| legal_status =
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-| routes_of_administration=
+| StdInChIKey = OSVMTWJCGUFAOD-KZQROQTASA-N
+| synonyms = <small>4-hydroxyandrost-4-ene-3,17-dione</small>
 }}
-'''Formestane''' belongs to a class of drugs known as [[aromatase inhibitors]].  It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.  It is available as an intramuscular depot injection (Lentaron).
+ __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Formestane''' ('''Lentaron''') is a type I, steroidal [[aromatase inhibitor]].  It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.  It is available as an intramuscular depot injection.
-Formestane is often used to suppress [[estrogen]] production from [[anabolic steroids]] or [[prohormones]].
+Formestane is often used to suppress [[estrogen]] production from [[anabolic steroids]] or [[prohormones]].  It also acts as a prohormone to [[4-hydroxytestosterone]], an active steroid which displays weak [[androgenic]] activity in addition to acting as a mild aromatase inhibitor.
-Formestane has poor oral bioavailability and as such is no longer popular as many orally available aromatase inhibitors have been developed.
+Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.
-It is available as a supplement for bodybuilders in transdermal formulations.
+It is selective.
+==References==
+{{Reflist|2}}
-{{Sex hormones}}
 [[Category:Aromatase inhibitors]]
-[[Category:Endocrinology]]
+[[Category:Drug]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}

Formestane: Difference between revisions

Latest revision as of 14:37, 13 April 2015

Overview

References

Navigation menu